scholarly journals Partial Agonists and Dual Disorders: Focus on Dual Schizophrenia

2021 ◽  
Vol 12 ◽  
Author(s):  
Lola Peris ◽  
Nestor Szerman
Keyword(s):  
Substance Use ◽  
Partial Agonist ◽  
Scientific Evidence ◽  
Epidemiological Studies ◽  
Psychotic Symptoms ◽  
Dual Disorders ◽  
Addictive Disorder ◽  
D3 Receptors ◽  
Partial Agonists ◽  
Dual Disorder

Dual disorder is a term applied to patients with an addictive disorder and other mental disorder. Epidemiological studies have established that dual disorders are an expectation rather than an exception. They are difficult to diagnose and treat and constitute a huge burden for both patients and their relatives and society. Current treatments are a combination of those needed to treat the addictive disorder with those focused on the co-occurring psychiatric disorder. Focusing specifically on schizophrenia, growing scientific evidence supports the existence of a shared vulnerability for substance use in these patients and those at risk. Various antipsychotics have been found to be useful in the treatment of psychotic symptoms and disorders; however, few effective treatments have been identified until now for substance use disorders in patients with dual schizophrenia. Partial agonism stands as a new pharmacological option available in recent years. Molecules with this kind of action may act as functional agonists or as antagonists, depending on the surrounding levels of the neurotransmitter. Studies have found their efficacy in schizophrenia, addiction, anxiety and depression. Certain partial agonist antipsychotics seem to have a role in the treatment of dual schizophrenia. That could be the case with cariprazine. Because of its higher affinity for dopaminergic D3 receptors compared to D2, a potential to prevent relapse to addiction, added to its antipsychotic efficacy, has been suggested. Here we briefly review current advances and future directions and introduce some personal insights into the role of partial agonists in co-occurring schizophrenia and substance use.

scholarly journals Traumatic Events in Dual Disorders: Prevalence and Clinical Characteristics

2020 ◽  
Vol 9 (8) ◽  
pp. 2553
Author(s):  
Laura Blanco ◽  
Albert Sió ◽  
Bridget Hogg ◽  
Ricard Esteve ◽  
Joaquim Radua ◽  
...  
Keyword(s):  
Substance Use ◽  
Risk Factor ◽  
Childhood Maltreatment ◽  
Traumatic Event ◽  
Psychological Trauma ◽  
Clinical Profile ◽  
Clinical Severity ◽  
Trauma Symptoms ◽  
Dual Disorders ◽  
Dual Disorder

Psychological trauma has been identified in substance use disorders (SUD) as a major etiological risk factor. However, detailed and systematic data about the prevalence and types of psychological trauma in dual disorders have been scarce to date. In this study, 150 inpatients were recruited and cross-sectionally screened on their substance use severity, psychological trauma symptoms, comorbidities, and clinical severity. One hundred patients fulfilled criteria for a dual disorder, while 50 patients were diagnosed with only SUD. Ninety-four percent of the whole sample suffered from at least one lifetime traumatic event. The prevalence rates of Posttraumatic Stress Disorder diagnosis for dual disorder and only SUD was around 20% in both groups; however, patients with dual disorder presented more adverse events, more childhood trauma, more dissociative symptoms, and a more severe clinical profile than patients with only SUD. Childhood maltreatment can also serve as a predictor for developing a dual disorder diagnosis and as a risk factor for developing a more complex and severe clinical profile. These data challenge our current clinical practice in the treatment of patients suffering from dual disorder or only SUD diagnosis and favor the incorporation of an additional trauma-focused therapy in this population. This may improve the prognosis and the course of the illness in these patients.

scholarly journals Special Issue: Diagnosis and Management of Addiction and Other Mental Disorders (Dual Disorders)

2021 ◽  
Vol 10 (6) ◽  
pp. 1307
Author(s):  
Ana Adan ◽  
Marta Torrens
Keyword(s):  
Substance Use ◽  
Mental Disorders ◽  
Mental Disorder ◽  
Substance Use Disorder ◽  
World Health ◽  
Special Issue ◽  
Dual Disorders ◽  
The World ◽  
Dual Disorder ◽  
Health Organization

The term “dual disorder” (DD) refers to the coexistence or concurrence of at least one substance use disorder (SUD) and another mental disorder in the same person, as the World Health Organization established in its lexicon of alcohol and drug terms [...]

Substance Use Portrayal in Oscar-nominated Movies

2020 ◽  
Vol 12 ◽  
Author(s):  
João Mauricio Castaldelli-Maia ◽  
Felipe Gil ◽  
Antonio Ventriglio ◽  
Julio Torales ◽  
Ligia Florio ◽  
...  
Keyword(s):  
Substance Use ◽  
Drug Use ◽  
Epidemiological Studies ◽  
Progressive Increase ◽  
Media Content ◽  
Media Content Analysis ◽  
Monitoring Drug ◽  
And Gender ◽  
Multiple Drugs ◽  
Gender Convergence

Background: As one of the forms of media and art most consumed in the world, Oscar-nominated movies should have their drug use representation monitored because of possibly influencing but also reflecting society’s behavior. Objective: To investigate drug use representation in scenes from movies nominated for the Academy Awards (Oscar) from 2008-2011, through media content analysis. Methods: 437 scenes from Oscar-nominated movies (best film, best actor and best actress categories) showing drug consumption and/or its effects were assessed. Each drug represented and identified in a given scene (i.e., drug use incident) was counted as a unit for the present study (n = 515). Survey settings were used to control for over- or under-estimation of the prevalence of a variable in a given year or movie. Results: All the Oscar-nominated movies portrayed at least one scene of drug use. There was a massive predominance of alcohol and tobacco in movies, with a high use among men who also use drugs, habitually or occasionally, but related to stress/tension, predominantly at home. However, there was a significant progressive increase in the use of drugs other than alcohol and tobacco, multiple drugs, and by women. Conclusion: These findings echo epidemiological studies on substance use in western countries, an overall trend towards greater home drug use representation and gender convergence since 1970, which increased since 2000. Monitoring drug use representation in Oscar-nominated movies may represent an important public health tool.

scholarly journals Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jonás Carmona-Pírez ◽  
Beatriz Poblador-Plou ◽  
Ignatios Ioakeim-Skoufa ◽  
Francisca González-Rubio ◽  
Luis Andrés Gimeno-Feliú ◽  
...  
Keyword(s):  
Substance Use ◽  
Chronic Conditions ◽  
Large Scale ◽  
Mental Health Problems ◽  
Epidemiological Studies ◽  
Chronic Obstructive ◽  
High Morbidity ◽  
Airway Diseases ◽  
Obstructive Sleep ◽  
Obstructive Airway Diseases

AbstractChronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis, and obstructive sleep apnea (OSA) are amongst the most common treatable and preventable chronic conditions with high morbidity burden and mortality risk. We aimed to explore the existence of multimorbidity clusters in patients with such diseases and to estimate their prevalence and impact on mortality. We conducted an observational retrospective study in the EpiChron Cohort (Aragon, Spain), selecting all patients with a diagnosis of allergic rhinitis, asthma, COPD, and/or OSA. The study population was stratified by age (i.e., 15–44, 45–64, and ≥ 65 years) and gender. We performed cluster analysis, including all chronic conditions recorded in primary care electronic health records and hospital discharge reports. More than 75% of the patients had multimorbidity (co-existence of two or more chronic conditions). We identified associations of dermatologic diseases with musculoskeletal disorders and anxiety, cardiometabolic diseases with mental health problems, and substance use disorders with neurologic diseases and neoplasms, amongst others. The number and complexity of the multimorbidity clusters increased with age in both genders. The cluster with the highest likelihood of mortality was identified in men aged 45 to 64 years and included associations between substance use disorder, neurologic conditions, and cancer. Large-scale epidemiological studies like ours could be useful when planning healthcare interventions targeting patients with chronic obstructive airway diseases and multimorbidity.

scholarly journals Does Cannabis, Cocaine and Alcohol Use Impact Differently on Adult Attention Deficit/Hyperactivity Disorder Clinical Picture?

2021 ◽  
Vol 10 (7) ◽  
pp. 1481
Author(s):  
Vincenza Spera ◽  
Alessandro Pallucchini ◽  
Marco Carli ◽  
Marco Maiello ◽  
Angelo G. I. Maremmani ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Substance Use ◽  
Attention Deficit ◽  
General Psychopathology ◽  
Hyperactivity Disorder ◽  
Legal Problems ◽  
Dual Disorder ◽  
Adhd Subtype

While the association between adult Attention Deficit/Hyperactivity Disorder (A-ADHD) and Substance Use Disorders (SUDs) has been widely explored, less attention has been dedicated to the various substance use variants. In a previous paper, we identified two variants: type 1 (use of stimulants/alcohol) and type 2 (use of cannabinoids). In this study, we compared demographic, clinical and symptomatologic features between Dual Disorder A-ADHD (DD/A-ADHD) patients according to our substance use typology, and A-ADHD without DD (NDD/A-ADHD) ones. NDD patients were more frequently diagnosed as belonging to inattentive ADHD subtype compared with type 1 DD/A-ADHD patients, but not with respect to type 2 DD/ADHD. NDD/A-ADHD patients showed less severe symptoms of hyperactivity/impulsivity than DD/A-ADHD type 1, but not type 2. Type 1 and type 2 patients shared the feature of displaying higher impulsiveness than NDD/A-ADHD ones. General psychopathology scores were more severe in type 2 DD/ADHD patients, whereas type 1 patients showed greater similarity to NDD/A-ADHD. Legal problems were more strongly represented in type 1 than in type 2 patients or NDD/A-ADHD ones. Our results suggest that type 1 and type 2 substance use differ in their effects on A-ADHD patients—an outcome that brings with it different likely implications in dealing with the diagnostic and therapeutic processes.

scholarly journals GPR40 reduces food intake and body weight through GLP-1

2017 ◽  
Vol 313 (1) ◽  
pp. E37-E47 ◽  
Author(s):  
Judith N. Gorski ◽  
Michele J. Pachanski ◽  
Joel Mane ◽  
Christopher W. Plummer ◽  
Sarah Souza ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Food Intake ◽  
Partial Agonist ◽  
Glucose Lowering ◽  
Partial Agonists ◽  
Lower Glucose ◽  
Glucagon Like Peptide 1 ◽  
Glucose Stimulated Insulin Secretion ◽  
G Protein Coupled

G protein-coupled receptor 40 (GPR40) partial agonists lower glucose through the potentiation of glucose-stimulated insulin secretion, which is believed to provide significant glucose lowering without the weight gain or hypoglycemic risk associated with exogenous insulin or glucose-independent insulin secretagogues. The class of small-molecule GPR40 modulators, known as AgoPAMs (agonist also capable of acting as positive allosteric modulators), differentiate from partial agonists, binding to a distinct site and functioning as full agonists to stimulate the secretion of both insulin and glucagon-like peptide-1 (GLP-1). Here we show that GPR40 AgoPAMs significantly increase active GLP-1 levels and reduce acute and chronic food intake and body weight in diet-induced obese (DIO) mice. These effects of AgoPAM treatment on food intake are novel and required both GPR40 and GLP-1 receptor signaling pathways, as demonstrated in GPR40 and GLP-1 receptor-null mice. Furthermore, weight loss associated with GPR40 AgoPAMs was accompanied by a significant reduction in gastric motility in these DIO mice. Chronic treatment with a GPR40 AgoPAM, in combination with a dipeptidyl peptidase IV inhibitor, synergistically decreased food intake and body weight in the mouse. The effect of GPR40 AgoPAMs on GLP-1 secretion was recapitulated in lean, healthy rhesus macaque demonstrating that the putative mechanism mediating weight loss translates to higher species. Together, our data indicate effects of AgoPAMs that go beyond glucose lowering previously observed with GPR40 partial agonist treatment with additional potential for weight loss.

scholarly journals Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
S. W. Seto ◽  
G. Y. Yang ◽  
H. Kiat ◽  
A. Bensoussan ◽  
Y. W. Kwan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chinese Medicine ◽  
Side Effects ◽  
Traditional Chinese Medicine ◽  
Cognitive Dysfunction ◽  
Scientific Evidence ◽  
Cerebrovascular Disorders ◽  
Blood Glucose Control ◽  
Epidemiological Studies ◽  
Therapeutic Benefits

Diabetes mellitus (DM) is a metabolic disorder affecting a large number of people worldwide. Numerous studies have demonstrated that DM can cause damage to multiple systems, leading to complications such as heart disease, cancer, and cerebrovascular disorders. Numerous epidemiological studies have shown that DM is closely associated with dementia and cognition dysfunction, with recent research focusing on the role of DM-mediated cerebrovascular damage in dementia. Despite the therapeutic benefits of antidiabetic agents for the treatment of DM-mediated cognitive dysfunction, most of these pharmaceutical agents are associated with various undesirable side-effects and their long-term benefits are therefore in doubt. Early evidence exists to support the use of traditional Chinese medicine (TCM) interventions, which tend to have minimal toxicity and side-effects. More importantly, these TCM interventions appear to offer significant effects in reducing DM-related complications beyond blood glucose control. However, more research is needed to further validate these claims and to explore their relevant mechanisms of action. The aims of this paper are (1) to provide an updated overview on the association between DM and cognitive dysfunction and (2) to review the scientific evidence underpinning the use of TCM interventions for the treatment and prevention of DM-induced cognitive dysfunction and dementia.

Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors

2008 ◽  
Vol 597 (1-3) ◽  
pp. 27-33 ◽  
Author(s):  
Yoshihiro Tadori ◽  
Robert A. Forbes ◽  
Robert D. McQuade ◽  
Tetsuro Kikuchi
Keyword(s):  
Partial Agonist ◽  
Agonist Activity ◽  
Dopamine D3 Receptors ◽  
D3 Receptors ◽  
Partial Agonist Activity ◽  
Dopamine D3

scholarly journals Association analysis between the C516T polymorphism in the 5-HT2A receptor gene and schizophrenia

2007 ◽  
Vol 65 (1) ◽  
pp. 11-14 ◽  
Author(s):  
Vivian Bertola ◽  
Quirino Cordeiro ◽  
Stevin Zung ◽  
Elisabete Cristina Miracca ◽  
Homero Vallada
Keyword(s):  
Atypical Antipsychotics ◽  
Receptor Gene ◽  
Epidemiological Studies ◽  
Case Control ◽  
Psychotic Symptoms ◽  
Serotonin 2A Receptor ◽  
Brazilian Sample ◽  
Control Approach ◽  
Serotonergic Drugs ◽  
Serotonin 2A

Data from epidemiological studies have demonstrated that genetics is an important risk factor for schizophrenia. Disturbances of serotonergic brain pathways have been implicated in the pathophysiology of schizophrenia. Some studies have suggested that the efficacy of atypical antipsychotics on schizophrenia treatment may be related to the serotonin 2A receptor (5-HT2A), and that serotonergic drugs may induce psychotic symptoms. Thus, the aim of this study was to investigate the association between the C516T polymorphism and schizophrenia in a Brazilian population composed by 246 patients and 315 healthy matched controls in a case-control approach. No statistically differences were observed in allelic (chi2=1.77, 1d.f., p=0.18) or genotypic (chi2=1.69, 2d.f., p=0.42) distributions between cases and controls. The results suggest that the C516T polymorphism of the 5-HT2A receptor gene is not related to the susceptibility for schizophrenia in our Brazilian sample.

Sign in / Sign up

Export Citation Format

Share Document